Vorinostat in Treating Patients With Kidney Cancer

NCT00278395 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

NIH

Sponsor class

Conditions

Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer

Interventions

DRUG: Vorinostat

Sponsor

National Cancer Institute (NCI)